Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH

Friedman, 2018, Mechanisms of NAFLD development and therapeutic strategies, Nature Medicine, 24, 908, 10.1038/s41591-018-0104-9 Anstee, 2020, Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort, Journal of Hepatology, 73, 505, 10.1016/j.jhep.2020.04.003 Ouchi, 2019, Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids, Cell Metabolism, 30, 374, 10.1016/j.cmet.2019.05.007 Hansen, 2020, Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis, BMC Gastroenterology, 20, 210, 10.1186/s12876-020-01356-2 Cleveland, 2018, Diagnostic challenges of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, Clinics in Liver Disease (Hoboken), 11, 98, 10.1002/cld.716 Davison, 2020, Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials, Journal of Hepatology, 73, 1322, 10.1016/j.jhep.2020.06.025 Chang, 2018, Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease, PLoS One, 13, 10.1371/journal.pone.0199166 Pokkalla, 2019, Machine learning models accurately interpret liver histology in patients with nonalcoholic steatohepatitis (Nash), Hepatology, 70, 121a Alonso, 2017, Metabolomic identification of subtypes of nonalcoholic steatohepatitis, Gastroenterology, 152, 1449, 10.1053/j.gastro.2017.01.015 Harrison, 2020, A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study, Lancent Gastroenterology & Hepatology, 5, 970, 10.1016/S2468-1253(20)30252-1 Daniels, 2019, ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis, Hepatology, 69, 1075, 10.1002/hep.30163 Newsome, 2020, FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study, Lancent Gastroenterology & Hepatology, 5, 362, 10.1016/S2468-1253(19)30383-8 Idilman, 2013, Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy, Radiology, 267, 767, 10.1148/radiol.13121360 Loomba, 2014, Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study, Hepatology, 60, 1920, 10.1002/hep.27362 Anstee, 2019, Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials, Hepatology, 70, 1521, 10.1002/hep.30842 Dulai, 2017, Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis, Hepatology, 65, 1557, 10.1002/hep.29085 Brunt, 2019, Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials, Hepatology, 70, 522, 10.1002/hep.30418 Patel, 2015, Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis, Clinical Gastroenterology and Hepatology, 13, 561, 10.1016/j.cgh.2014.08.039 Vilar-Gomez, 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005 Promrat, 2010, Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis, Hepatology, 51, 121, 10.1002/hep.23276 Nicklas, 2012, Successful weight loss among obese U.S. adults, American Journal of Preventive Medicine, 42, 481, 10.1016/j.amepre.2012.01.005 Koutoukidis, 2019, Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis, JAMA International Medicine, 179, 1262, 10.1001/jamainternmed.2019.2248 Khera, 2016, Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis, JAMA, 315, 2424, 10.1001/jama.2016.7602 O'Neil, 2018, Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial, Lancet, 392, 637, 10.1016/S0140-6736(18)31773-2 Frias, 2018, Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial, Lancet, 392, 2180, 10.1016/S0140-6736(18)32260-8 Schauer, 2017, Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes, New England Journal of Medicine, 376, 641, 10.1056/NEJMoa1600869 Carlsson, 2020, Life expectancy after bariatric surgery in the Swedish obese subjects study, New England Journal of Medicine, 383, 1535, 10.1056/NEJMoa2002449 Yoshino, 2020, Effects of diet versus gastric bypass on metabolic function in diabetes, New England Journal of Medicine, 383, 721, 10.1056/NEJMoa2003697 Lassailly, 2020, Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis, Gastroenterology, 159, 1290, 10.1053/j.gastro.2020.06.006 Evans, 2014, Nuclear receptors, RXR, and the big bang, Cell, 157, 255, 10.1016/j.cell.2014.03.012 Cave, 2016, Nuclear receptors and nonalcoholic fatty liver disease, Biochimica et Biophysica Acta, 1859, 1083, 10.1016/j.bbagrm.2016.03.002 Bakris, 2020, Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes, New England Journal of Medicine, 383, 2219, 10.1056/NEJMoa2025845 Biondi, 2010, Thyroid and obesity: an intriguing relationship, Journal of Clinical Endocrinology & Metabolism, 95, 3614, 10.1210/jc.2010-1245 Mullur, 2014, Thyroid hormone regulation of metabolism, Physiological Reviews, 94, 355, 10.1152/physrev.00030.2013 Ochs, 2008, Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality, Annals of Internal Medicine, 148, 832, 10.7326/0003-4819-148-11-200806030-00225 Nascimento, 2006, Structural rearrangements in the thyroid hormone receptor hinge domain and their putative role in the receptor function, Journal of Molecular Biology, 360, 586, 10.1016/j.jmb.2006.05.008 Chiellini, 1998, A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor, Chemistry & Biology, 5, 299, 10.1016/S1074-5521(98)90168-5 Berkenstam, 2008, The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans, Proceedings of the National Academy of Sciences of the U S A, 105, 663, 10.1073/pnas.0705286104 Lammel Lindemann, 2016, Sobetirome: the past, present and questions about the future, Expert Opinion on Therapeutic Targets, 20, 145, 10.1517/14728222.2016.1090429 Mansouri, 2018, Mitochondrial dysfunction and signaling in chronic liver diseases, Gastroenterology, 155, 629, 10.1053/j.gastro.2018.06.083 Williams, 2013, Thyroid hormone actions in cartilage and bone, European Thyroid Journal, 2, 3 Kelly, 2014, Journal of Medicinal Chemistry, 57, 3912, 10.1021/jm4019299 Taub, 2013, Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist, Atherosclerosis, 230, 373, 10.1016/j.atherosclerosis.2013.07.056 Harrison, 2019, Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, Lancet, 394, 2012, 10.1016/S0140-6736(19)32517-6 Erion, 2007, Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index, Proceedings of the National Academy of Sciences of the U S A, 104, 15490, 10.1073/pnas.0702759104 Erion, 2004, Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver, Journal of the American Chemical Society, 126, 5154, 10.1021/ja031818y Lian, 2020, VK2809, a novel liver-directed thyroid receptor agonist, produces durable reductions in liver fat in patients with non-alcoholic fatty liver disease: results of 4-week follow-up assessment from a 12- week phase 2 randomized, placebo-controlled trial, Journal of Hepatology, 73, S53, 10.1016/S0168-8278(20)30652-8 Matsubara, 2013, FXR signaling in the enterohepatic system, Molecular and Cellular Endocrinology, 368, 17, 10.1016/j.mce.2012.05.004 Ma, 2006, Farnesoid X receptor is essential for normal glucose homeostasis, Journal of Clinical Investigation, 116, 1102, 10.1172/JCI25604 Zhang, 2006, Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice, Proceedings of the National Academy of Sciences of the U S A, 103, 1006, 10.1073/pnas.0506982103 Kim, 2018, Glucagon receptor signaling regulates energy metabolism via hepatic farnesoid X receptor and fibroblast growth factor 21, Diabetes, 67, 1773, 10.2337/db17-1502 Zhou, 2019, Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis, The Journal of Lipid Research, 60, 550, 10.1194/jlr.M089961 Anfuso, 2020, Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model, Scientific Reports, 10, 1699, 10.1038/s41598-020-58562-x Jiang, 2015, Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease, Journal of Clinical Investigation, 125, 386, 10.1172/JCI76738 Jiang, 2015, Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction, Nature Communications, 6, 10166, 10.1038/ncomms10166 Thomas, 2009, TGR5-mediated bile acid sensing controls glucose homeostasis, Cell Metabolism, 10, 167, 10.1016/j.cmet.2009.08.001 Velazquez-Villegas, 2018, TGR5 signalling promotes mitochondrial fission and beige remodelling of white adipose tissue, Nature Communications, 9, 245, 10.1038/s41467-017-02068-0 Lieu, 2014, The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice, Gastroenterology, 147, 1417, 10.1053/j.gastro.2014.08.042 Pellicciari, 2009, Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity, Journal of Medicinal Chemistry, 52, 7958, 10.1021/jm901390p Pellicciari, 2002, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity, Journal of Medicinal Chemistry, 45, 3569, 10.1021/jm025529g Mudaliar, 2013, Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease, Gastroenterology, 145, 574, 10.1053/j.gastro.2013.05.042 Neuschwander-Tetri, 2015, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, Lancet, 385, 956, 10.1016/S0140-6736(14)61933-4 Younossi, 2019, Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial, Lancet, 394, 2184, 10.1016/S0140-6736(19)33041-7 An, 2020, A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction, Liver International, 40, 1655, 10.1111/liv.14490 Ratziu, 2020, EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a argon-1 study, Journal of Hepatology, 73, S56, 10.1016/S0168-8278(20)30657-7 Tully, 2017, Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH), Journal of Medicinal Chemistry, 60, 9960, 10.1021/acs.jmedchem.7b00907 Badman, 2020, Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non-bile acid FXR agonist tropifexor (LJN452) in healthy volunteers, Clinical Pharmacology Drug Device, 9, 395, 10.1002/cpdd.762 Sanyal, 2019, Tropifexor, a farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis: interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR, Journal of Hepatology, 70, E796, 10.1016/S0618-8278(19)31587-7 Chianelli, 2020, Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis, Journal of Medicinal Chemistry, 63, 3868, 10.1021/acs.jmedchem.9b01621 Aspinall, 2020, Nidufexor, a non-bile acid FXR agonist, decreases ALT and hepatic fat fraction in patients with NASH after 12 weeks dosing, Journal of Hepatology, 73, S4, 10.1016/S0168-8278(20)30570-5 Patel, 2020, Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial, Hepatology, 72, 58, 10.1002/hep.31205 Lawitz, 2020, MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with nonalcoholic steatohepatitis: a 12-week, randomized, placebocontrolled study, Journal of Hepatology, 73, S132 Targher, 2016, Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis, Journal of Hepatology, 65, 589, 10.1016/j.jhep.2016.05.013 Tuckermann, 1999, The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin, The Journal of Cell Biology, 147, 1365, 10.1083/jcb.147.7.1365 Hemmer, 2019, E47 modulates hepatic glucocorticoid action, Nature Communications, 10, 306, 10.1038/s41467-018-08196-5 De Bosscher, 2005, A fully dissociated compound of plant origin for inflammatory gene repression, Proceedings of the National Academy of Sciences of the U S A, 102, 15827, 10.1073/pnas.0505554102 Lehrke, 2005, The many faces of PPARgamma, Cell, 123, 993, 10.1016/j.cell.2005.11.026 Son, 2010, PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation, Journal of Clinical Investigation, 120, 3443, 10.1172/JCI40905 Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, New England Journal of Medicine, 356, 2457, 10.1056/NEJMoa072761 Lago, 2007, Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials, Lancet, 370, 1129, 10.1016/S0140-6736(07)61514-1 Chang, 2004, Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy, Pharmacoepidemiology and Drug Safety, 13, 417, 10.1002/pds.977 Nissen, 2005, Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus, JAMA, 294, 2581, 10.1001/jama.294.20.joc50147 Goke, 2007, The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes, Diabetes and Vascular Disease Research, 4, 204, 10.3132/dvdr.2007.041 Sanyal, 2010, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, New England Journal of Medicine, 362, 1675, 10.1056/NEJMoa0907929 Sohda, 1990, Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones, Arzneimittelforschung, 40, 37 Ratziu, 2010, Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial, Hepatology, 51, 445, 10.1002/hep.23270 Ratziu, 2008, Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial, Gastroenterology, 135, 100, 10.1053/j.gastro.2008.03.078 Goldberg, 2005, A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia, Diabetes Care, 28, 1547, 10.2337/diacare.28.7.1547 Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9 Kernan, 2016, Pioglitazone after ischemic stroke or transient ischemic attack, New England Journal of Medicine, 374, 1321, 10.1056/NEJMoa1506930 Jain, 2015, Saroglitazar, a novel PPARalpha/gamma agonist with predominant PPARalpha activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models, Pharmacology Research Perspectives, 3, 10.1002/prp2.136 Dietz, 2012, Comparative molecular profiling of the PPARalpha/gamma activator aleglitazar: PPAR selectivity, activity and interaction with cofactors, ChemMedChem, 7, 1101, 10.1002/cmdc.201100598 Gawrieh, 2019, A phase 2, prospective, multicenter, double-blind, randomized study OF saroglitazar magnesium 1 MG, 2 MG or 4 MG versus placebo IN patients with nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis (evidences IV), Hepatology, 70, 1484A Ratziu, 2016, Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening, Gastroenterology, 150, 1147, 10.1053/j.gastro.2016.01.038 Genfit, 2020 Boubia, 2018, Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) alpha/gamma/delta triple activators: discovery of lanifibranor, a new antifibrotic clinical candidate, Journal of Medicinal Chemistry, 61, 2246, 10.1021/acs.jmedchem.7b01285 Inventiva, 2020 Yamazaki, 2007, Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists, Bioorganic & Medicinal Chemistry Letters, 17, 4689, 10.1016/j.bmcl.2007.05.066 Ishibashi, 2016, Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial, Atherosclerosis, 249, 36, 10.1016/j.atherosclerosis.2016.02.029 Araki, 2018, Effects of pemafibrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial, Diabetes Care, 41, 538, 10.2337/dc17-1589 Araki, 2019, Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study, Diabetes, Obesity and Metabolism, 21, 1737, 10.1111/dom.13686 Jones, 2017, Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study, Lancent Gastroenterology & Hepatology, 2, 716, 10.1016/S2468-1253(17)30246-7 Harrison, 2020, A 52-WEEK multi-center double-blind randomized phase 2 study OF seladelpar, a potent and selective peroxisome proliferator-activated receptor delta (PPAR-DELTA) agonist, IN patients with nonalcoholic steatohepatitis (NASH), Hepatology, 72, 131A Byrne, 2015, NAFLD: a multisystem disease, Journal of Hepatology, 62, S47, 10.1016/j.jhep.2014.12.012 Tripathi, 2018, The gut-liver axis and the intersection with the microbiome, Nature Reviews Gastroenterology & Hepatology, 15, 397, 10.1038/s41575-018-0011-z Falutz, 2008, Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation, AIDS, 22, 1719, 10.1097/QAD.0b013e32830a5058 Fourman, 2017, Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV, AIDS, 31, 2253, 10.1097/QAD.0000000000001614 Stanley, 2019, Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial, Lancet HIV, 6, e821, 10.1016/S2352-3018(19)30338-8 Fourman, 2020, Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD, JCI Insight, 5, 10.1172/jci.insight.140134 Pan, 2020, Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease, Clinical Endocrinology (Oxf) Benito, 1991, Sex differences in growth hormone response to growth hormone-releasing hormone, Journal of Endocrinological Investigation, 14, 265, 10.1007/BF03346809 Hudson, 2010, Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type determine pulsatile growth hormone secretion in healthy women: studies using submaximal agonist drive and an estrogen clamp, Journal of Clinical Endocrinology & Metabolism, 95, 353, 10.1210/jc.2009-1769 Lonardo, 2019, Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps, Hepatology, 70, 1457, 10.1002/hep.30626 Nicholes, 2002, A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice, American Journal of Pathology, 160, 2295, 10.1016/S0002-9440(10)61177-7 Gaich, 2013, The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes, Cell Metabolism, 18, 333, 10.1016/j.cmet.2013.08.005 Talukdar, 2016, A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects, Cell Metabolism, 23, 427, 10.1016/j.cmet.2016.02.001 Adams, 2012, The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue, Molecular Metabolism, 2, 31, 10.1016/j.molmet.2012.08.007 Foltz, 2012, Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex, Science Translational Medicine, 4, 10.1126/scitranslmed.3004690 Zhou, 2014, Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19, Cancer Research, 74, 3306, 10.1158/0008-5472.CAN-14-0208 Zhou, 2017, Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis, Nature Communications, 8, 15433, 10.1038/ncomms15433 Harrison, 2020, Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis, Gastroenterology, 160, 219, 10.1053/j.gastro.2020.08.004 Charles, 2019, Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study, Obesity (Silver Spring), 27, 41, 10.1002/oby.22344 Sanyal, 2019, Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial, Lancet, 392, 2705, 10.1016/S0140-6736(18)31785-9 Bio89, 2020 Stanislaus, 2017, A novel fc-FGF21 with improved resistance to proteolysis, increased affinity toward beta-klotho, and enhanced efficacy in mice and cynomolgus monkeys, Endocrinology, 158, 1314, 10.1210/en.2016-1917 Kaufman, 2020, AKR-001, an fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients, Cell Reports Medicine, 1, 10.1016/j.xcrm.2020.100057 Harrison, 2018, NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, Lancet, 391, 1174, 10.1016/S0140-6736(18)30474-4 Akero Therapeutics, 2020 Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, New England Journal of Medicine, 375, 1834, 10.1056/NEJMoa1607141 Pratley, 2018, Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial, Lancent Diabetes Endocrinology, 6, 275, 10.1016/S2213-8587(18)30024-X Mells, 2012, Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet, American Journal of Physiology - Gastrointestinal and Liver Physiology, 302, G225, 10.1152/ajpgi.00274.2011 Trevaskis, 2012, Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice, American Journal of Physiology - Gastrointestinal and Liver Physiology, 302, G762, 10.1152/ajpgi.00476.2011 Gupta, 2010, Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway, Hepatology, 51, 1584, 10.1002/hep.23569 Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet, 387, 679, 10.1016/S0140-6736(15)00803-X Pratley, 2019, Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial, Lancet, 394, 39, 10.1016/S0140-6736(19)31271-1 Nauck, 2016, A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes, Diabetes Care, 39, 231, 10.2337/dc15-0165 Newsome, 2020, A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis, New England Journal of Medicine Finan, 2013, Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans, Science Translational Medicine, 5, 10.1126/scitranslmed.3007218 Coskun, 2018, LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept, Molecular Metabolism, 18, 3, 10.1016/j.molmet.2018.09.009 Frias, 2017, The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes, Cell Metabolism, 26, 343, 10.1016/j.cmet.2017.07.011 Frias, 2020, Diabetes, Obesity and Metabolism, 22, 938, 10.1111/dom.13979 Moller, 2016, Glucose-Dependent insulinotropic polypeptide is associated with lower low-density lipoprotein but unhealthy fat distribution, independent of insulin: the ADDITION-PRO study, Journal of Clinical Endocrinology & Metabolism, 101, 485, 10.1210/jc.2015-3133 Hartman, 2020, Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes, Diabetes Care, 43, 1352, 10.2337/dc19-1892 Samms, 2020, How may GIP enhance the therapeutic efficacy of GLP-1?, Trends in Endocrinology and Metabolism, 31, 410, 10.1016/j.tem.2020.02.006 Day, 2009, A new glucagon and GLP-1 co-agonist eliminates obesity in rodents, Nature Chemical Biology, 5, 749, 10.1038/nchembio.209 Pocai, 2009, Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, Diabetes, 58, 2258, 10.2337/db09-0278 Henderson, 2016, Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates, Diabetes, Obesity and Metabolism, 18, 1176, 10.1111/dom.12735 Finan, 2015, A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents, Nature Medicine, 21, 27, 10.1038/nm.3761 Boland, 2020, Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis, Nature Metabolism, 2, 413, 10.1038/s42255-020-0209-6 Valdecantos, 2017, A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice, Hepatology, 65, 950, 10.1002/hep.28962 Ambery, 2018, MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study, Lancet, 391, 2607, 10.1016/S0140-6736(18)30726-8 Nahra, 2020, Effects of cotadutide on biomarkers of non-alcoholic steatohepatitis in overweight or obese subjects with type 2 diabetes mellitus: a 54-week analysis of a randomized phase 2b study, Journal of Hepatology, 73, S54, 10.1016/S0168-8278(20)30655-3 Abdelmalek, 2020, HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: a Phase 1b/2a, multicenter, randomized, placebo-controlled trial, Journal of Hepatology, 73, S124, 10.1016/S0168-8278(20)30765-0 Eriksson, 2020, Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes, Scientific Reports, 10, 16758, 10.1038/s41598-020-73815-5 Ekstedt, 2015, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, 61, 1547, 10.1002/hep.27368 Dufour, 2020, Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges, Gut, 69, 1877, 10.1136/gutjnl-2019-319104 Finan, 2012, Targeted estrogen delivery reverses the metabolic syndrome, Nature Medicine, 18, 1847, 10.1038/nm.3009 Quarta, 2017, Molecular integration of incretin and glucocorticoid action reverses immunometabolic dysfunction and obesity, Cell Metabolism, 26, 620, 10.1016/j.cmet.2017.08.023 Ammala, 2018, Targeted delivery of antisense oligonucleotides to pancreatic beta-cells, Science Advance, 4 Wittrisch, 2020, NPY1R-targeted peptide-mediated delivery of a dual PPARalpha/gamma agonist to adipocytes enhances adipogenesis and prevents diabetes progression, Molecular Metabolism, 31, 163, 10.1016/j.molmet.2019.11.009 Finan, 2016, Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease, Cell, 167, 843, 10.1016/j.cell.2016.09.014 Vatner, 2013, Thyroid hormone receptor-beta agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways, American Journal of Physiology. Endocrinology and Metabolism, 305, E89, 10.1152/ajpendo.00573.2012 Ali, 2015, Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction, Molecular Metabolism, 4, 132, 10.1016/j.molmet.2014.11.005 Estes, 2018, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 67, 123, 10.1002/hep.29466 Loomba, 2013, The global NAFLD epidemic, Nature Reviews Gastroenterology & Hepatology, 10, 686, 10.1038/nrgastro.2013.171